Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightThe results of our study demonstrated that, in the 24- and 48-hour applications of the doses of 30 and 60 μM, the antioxidant system could not compensate and the cells exposed to oxidative stress.
📌 3 Maddede Bu Makale
Abstract
Depression is one of the prevalent psychiatric diseases in Turkey and the world. Fluvoxamine is a strong selective serotonin reuptake inhibitor (SSRI) that is used as an antidepressant. No study investigating the doses of Fluvoxamine treatment that may lead to a disruption in the oxidant-antioxidant balance on the cellular level in addition to its beneficial effects has been found in the literature. For this purpose, by creating Fluvoxamine application groups at the doses of 7.5, 15, 30 and 60 μM and durations of 24 and 48 hours on human lymphocyte cell cultures, we investigated the total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI). According to the results of the study, the TOS levels of all dose groups increased significantly in the 24- and 48-hour applications (p<0.05). While the TAS levels significantly increased in the 24-hour application of the doses of 7.5 and 15 μM and 48-application of the dose of 7.5 μM, they significantly decreased in the 24- and 48-hour applications of the doses of 30 and 60 μM (p<0.05). The OSI level increased significantly in the 24- and 48-hour applications of the doses of 30 and 60 μM. The results of our study demonstrated that, in the 24- and 48-hour applications of the doses of 30 and 60 μM, the antioxidant system could not compensate and the cells exposed to oxidative stress.